We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer to Stall R&D for Alzheimer's/Parkinson's, Cut Jobs
Read MoreHide Full Article
Pfizer, Inc. (PFE - Free Report) reportedly said in a statement that it will end R&D efforts in the Alzheimer’s and Parkinson’s disease areas, which will result in about 300 layoffs.
The decision to end the neuroscience-discovery program will mainly affect employees at facilities in Andover and Cambridge, MA, and Groton, CT. Pfizer, however, intends to continue development of pain candidate, tanezumab, which it is developing in late-stage studies in partnership with Eli Lilly (LLY - Free Report) , label expansion efforts for pain drug Lyrica and its rare disease program.
Shares of Pfizer have risen 10.2% in the past year, comparing unfavorably with a 16.5% increase for the industry.
The successful development of therapies for the treatment of Alzheimer’s disease is challenging and we note that several companies have failed in this regard.
In fact Pfizer itself shelved its late-stage Alzheimer’s candidate, bapineuzumab IV after it failed two phase III studies. Pfizer was developing the candidate in collaboration with Johnson & Johnson (JNJ - Free Report) and Elan Corporation.
In November 2016, Lilly’s anti-amyloid candidate solanezumab failed to meet the primary endpoint in a late-stage AD study. Lilly decided to drop the development of solanezumab. Lillyalso suffered a major setback in August 2010, when it had to halt the development of another phase III Alzheimer’s candidate, semagacestat.
Last month, Biogen, Inc. (BIIB - Free Report) announced that an Alzheimer’s disease study on BAN2401 failed to show early positive which raised investor concern about the candidate’s chances of success.
Pfizer plans to use savings from the terminated programs to re-allocate spend on potentially more fruitful pipeline projects.
Pfizer expects approximately 25 to 30 drug approvals over the next five years, of which around 15 products have blockbuster potential. These include line-extensions for cancer drugs, Xtandi and Ibrance as well as rheumatoid arthritis drug, Xeljanz. Half of these potential blockbusters are expected to receive approval by 2020.
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Pfizer to Stall R&D for Alzheimer's/Parkinson's, Cut Jobs
Pfizer, Inc. (PFE - Free Report) reportedly said in a statement that it will end R&D efforts in the Alzheimer’s and Parkinson’s disease areas, which will result in about 300 layoffs.
The decision to end the neuroscience-discovery program will mainly affect employees at facilities in Andover and Cambridge, MA, and Groton, CT. Pfizer, however, intends to continue development of pain candidate, tanezumab, which it is developing in late-stage studies in partnership with Eli Lilly (LLY - Free Report) , label expansion efforts for pain drug Lyrica and its rare disease program.
Shares of Pfizer have risen 10.2% in the past year, comparing unfavorably with a 16.5% increase for the industry.
The successful development of therapies for the treatment of Alzheimer’s disease is challenging and we note that several companies have failed in this regard.
In fact Pfizer itself shelved its late-stage Alzheimer’s candidate, bapineuzumab IV after it failed two phase III studies. Pfizer was developing the candidate in collaboration with Johnson & Johnson (JNJ - Free Report) and Elan Corporation.
In November 2016, Lilly’s anti-amyloid candidate solanezumab failed to meet the primary endpoint in a late-stage AD study. Lilly decided to drop the development of solanezumab. Lillyalso suffered a major setback in August 2010, when it had to halt the development of another phase III Alzheimer’s candidate, semagacestat.
Last month, Biogen, Inc. (BIIB - Free Report) announced that an Alzheimer’s disease study on BAN2401 failed to show early positive which raised investor concern about the candidate’s chances of success.
Pfizer plans to use savings from the terminated programs to re-allocate spend on potentially more fruitful pipeline projects.
Pfizer expects approximately 25 to 30 drug approvals over the next five years, of which around 15 products have blockbuster potential. These include line-extensions for cancer drugs, Xtandi and Ibrance as well as rheumatoid arthritis drug, Xeljanz. Half of these potential blockbusters are expected to receive approval by 2020.
Pfizer carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>